Meningococcal Disease and Menactra Vaccine
Wider Student Use Is Urged for New Meningitis Vaccine[ ... Read the full article ... ]
By LAWRENCE K. ALTMAN
The New York Times
Published: May 27, 2005
The Centers for Disease Control and Prevention recommended yesterday wider use of a new meningitis vaccine for adolescents and college freshmen.
The vaccine, sold as Menactra by Sanofi Pasteur, protects against infections caused by meningococcal bacteria. Such infections include a form of meningitis that can be rapidly fatal.
For the first time, the diseases center, a federal agency in Atlanta, recommended that all 11- and 12-year-olds be routinely immunized against meningococcal disease.
The agency also recommended using Menactra to protect high school freshmen or children younger than 15, whichever comes earlier.
In a third recommendation, the agency recommended that all college freshmen living in dormitories be immunized against meningococcal disease. The new recommendation strengthened an earlier one that said freshmen should consider such protection.
Anthony H. Risser | neuroscience | neuropsychology | brain | neurology